Euroapi S.A.

ENXTPA:EAPI Lagerbericht

Marktkapitalisierung: €130.4m

Euroapi Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Die Gewinne von Euroapi sind mit einer durchschnittlichen Jahresrate von -51.8% zurückgegangen, während die Gewinne der Branche Pharmaceuticals um 5.7% pro Jahr zurückgingen. Die Umsätze sind zurückgegangen mit einer durchschnittlichen Jahresrate von 1.4%.

Wichtige Informationen

-51.85%

Wachstumsrate der Gewinne

-51.71%

EPS-Wachstumsrate

Pharmaceuticals Wachstum der Industrie16.27%
Wachstumsrate der Einnahmen-1.40%
Eigenkapitalrendite-26.80%
Netto-Marge-24.77%
Nächste Ertragsaktualisierung28 Jul 2026

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

EAPI: Lower Demand And Portfolio Cuts Will Weigh On Future Earnings

Analysts have cut their price target on Euroapi to €1 from €2, with the change framed around more cautious assumptions despite essentially unchanged fair value, discount rate, revenue growth, profit margin and future P/E inputs in the latest update. Analyst Commentary Bearish analysts cutting the price target on Euroapi to €1 from €2 are signaling a more cautious stance around the stock, even though their core valuation inputs such as fair value frameworks, discount rate, revenue growth, profit margin and future P/E assumptions are described as essentially unchanged.

EAPI: Future Cost Controls May Unlock Upside Despite 2026 Sales Headwinds

Analysts now see Euroapi's fair value closer to €2.90, down from €3.50, aligning with a series of lower Street price targets that most recently moved from €2.50 to €2 and then to €1. Analyst Commentary The recent cuts in fair value and Street targets to around €1 to €2 signal a cautious stance from research desks, with the most recent change bringing the target to €1 and maintaining a Sell view.

EAPI: Weaker 2026 Outlook And Portfolio Cuts Will Pressure Earnings Quality

Analysts have cut their price target on Euroapi to €1 from €2, with the shift broadly tied to ongoing caution reflected in recent research commentary that maintains a Sell stance and modest adjustments to revenue growth and profit margin assumptions. Analyst Commentary Recent research updates highlight a series of price target cuts on Euroapi, with bearish analysts reducing their fair value estimates while maintaining a cautious stance on the shares.

EAPI: Weaker 2025 Guidance Will Pressure Margins And Future Earnings Quality

Analysts have cut their Euroapi price target from €2 to €1, reflecting updated assumptions that now factor in lower revenue growth expectations, much slimmer profit margins, and a significantly higher future P/E multiple. Analyst Commentary Recent price target revisions point to a cautious stance from bearish analysts, who appear focused on execution risks and the implications for Euroapi's valuation.

EAPI: Lower 2025 Guidance And Reduced Multiple Will Shape Return Profile

Analysts have trimmed their price target on Euroapi to €2 from €2.50, citing updated assumptions on modest revenue growth, slightly higher profit margins, and a marginally lower future P/E multiple. Analyst Commentary Recent research points to a more cautious stance on Euroapi, with bearish analysts trimming their price targets to €2.

EAPI: Lower 2025 Outlook And Cautious Stance Will Shape Return Profile

Analysts have lowered their price target on Euroapi from €2.50 to €2, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E that collectively suggest a more cautious valuation stance. Analyst Commentary Bearish analysts have recently cut their price target on Euroapi from €2.50 to €2.

EAPI: Execution Risks And Lower Outlook Will Shape Future Return Profile

Narrative update Analysts have trimmed their price target on Euroapi by €0.50 to €2.00, citing updated assumptions on revenue growth, profit margins and forward P/E that keep their stance cautious on the shares. Analyst Commentary Recent research has reinforced a cautious stance on Euroapi, with bearish analysts trimming their price targets to €2.00.

EAPI: Lower Profitability Assumptions And New Partnership Will Shape Future Returns

Analysts have trimmed their price target on Euroapi to €2 from €2.50, citing softer assumptions around revenue growth, profit margins and a higher future P/E multiple as the key drivers of the reset. Analyst Commentary Bearish analysts are signalling a cautious stance on Euroapi by aligning around a lower price target of €2, narrowed from €2.50.

EAPI: Higher Discount Rate Will Outweigh Benefits From New Corticosteroid Partnership

Analysts have slightly reduced their Euroapi price target, reflecting a modest reassessment of fair value. This adjustment accounts for a higher discount rate, even as long term profit margin assumptions edge up and revenue declines appear marginally less severe.

Calculating The Intrinsic Value Of Euroapi S.A. (EPA:EAPI)

Dec 18
Calculating The Intrinsic Value Of Euroapi S.A. (EPA:EAPI)

Euroapi S.A. (EPA:EAPI) Not Doing Enough For Some Investors As Its Shares Slump 26%

Dec 18
Euroapi S.A. (EPA:EAPI) Not Doing Enough For Some Investors As Its Shares Slump 26%

Euroapi (EPA:EAPI) Has Debt But No Earnings; Should You Worry?

Oct 03
Euroapi (EPA:EAPI) Has Debt But No Earnings; Should You Worry?

Euroapi S.A. (EPA:EAPI) Just Released Its Interim Results And Analysts Are Updating Their Estimates

Aug 02
Euroapi S.A. (EPA:EAPI) Just Released Its Interim Results And Analysts Are Updating Their Estimates
User avatar

Capacity Expansion And Efficiency Improvements Will Shape Future Success

Euroapi focuses on high-margin differentiated APIs and CDMO services to boost sustainable revenue and profit margins through strategic project expansions.

Analyst Estimates: Here's What Brokers Think Of Euroapi S.A. (EPA:EAPI) After Its Annual Report

Mar 06
Analyst Estimates: Here's What Brokers Think Of Euroapi S.A. (EPA:EAPI) After Its Annual Report

Euroapi S.A.'s (EPA:EAPI) Intrinsic Value Is Potentially 25% Below Its Share Price

Oct 04
Euroapi S.A.'s (EPA:EAPI) Intrinsic Value Is Potentially 25% Below Its Share Price

There's No Escaping Euroapi S.A.'s (EPA:EAPI) Muted Revenues Despite A 32% Share Price Rise

Jul 29
There's No Escaping Euroapi S.A.'s (EPA:EAPI) Muted Revenues Despite A 32% Share Price Rise

Euroapi S.A. (EPA:EAPI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

May 24
Euroapi S.A. (EPA:EAPI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Euroapi (EPA:EAPI) Seems To Be Using A Lot Of Debt

Apr 10
Euroapi (EPA:EAPI) Seems To Be Using A Lot Of Debt

Little Excitement Around Euroapi S.A.'s (EPA:EAPI) Revenues As Shares Take 31% Pounding

Mar 03
Little Excitement Around Euroapi S.A.'s (EPA:EAPI) Revenues As Shares Take 31% Pounding

Euroapi S.A. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts

Mar 02
Euroapi S.A. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts

A Look At The Fair Value Of Euroapi S.A. (EPA:EAPI)

Dec 21
A Look At The Fair Value Of Euroapi S.A. (EPA:EAPI)

Analysts Are Updating Their Euroapi S.A. (EPA:EAPI) Estimates After Its Half-Yearly Results

Aug 04
Analysts Are Updating Their Euroapi S.A. (EPA:EAPI) Estimates After Its Half-Yearly Results

Is Euroapi S.A. (EPA:EAPI) Trading At A 49% Discount?

Aug 02
Is Euroapi S.A. (EPA:EAPI) Trading At A 49% Discount?

Euroapi S.A.'s (EPA:EAPI) Subdued P/S Might Signal An Opportunity

Jun 16
Euroapi S.A.'s (EPA:EAPI) Subdued P/S Might Signal An Opportunity

An Intrinsic Calculation For Euroapi S.A. (EPA:EAPI) Suggests It's 37% Undervalued

Jan 25
An Intrinsic Calculation For Euroapi S.A. (EPA:EAPI) Suggests It's 37% Undervalued

Aufschlüsselung der Einnahmen und Ausgaben

Wie Euroapi Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.


Gewinn- und Umsatzhistorie

ENXTPA:EAPI Einnahmen, Ausgaben und Erträge (EUR Millions)
DatumEinnahmenGewinnAllgemeine und VerwaltungskostenF&E-Ausgaben
31 Dec 25853-21111927
30 Sep 25868-16812025
30 Jun 25883-12412122
31 Mar 25901-12712524
31 Dec 24919-13113026
30 Sep 24945-20913228
30 Jun 24971-28713530
31 Mar 24995-23813430
31 Dec 231,019-19013430
30 Sep 231,006-7913527
30 Jun 239943113724
31 Mar 23987813323
31 Dec 22981-1512922
30 Sep 22962-312020
30 Jun 229441011018
31 Mar 22918110018
31 Dec 21893-89017
31 Dec 20945-67120
31 Dec 1991636616

Qualität der Erträge: EAPI ist derzeit unrentabel.

Wachsende Gewinnspanne: EAPI ist derzeit unrentabel.


Analyse von freiem Cashflow und Gewinn


Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: EAPI ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 51.8% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von EAPI verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: EAPI ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Pharmaceuticals (3.9%) erschwert.


Eigenkapitalrendite

Hohe Eigenkapitalrendite: EAPI hat eine negative Eigenkapitalrendite (-26.8%), da es derzeit unrentabel ist.


Kapitalrendite


Rendite auf das eingesetzte Kapital


Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/04/30 19:27
Aktienkurs zum Tagesende2026/04/30 00:00
Gewinne2025/12/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Euroapi S.A. wird von 11 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Justin Steven SmithBernstein
Patrick Andrew WoodBofA Global Research
Fynn ScherzlerDeutsche Bank